Format

Send to

Choose Destination
Mol Immunol. 2015 Oct;67(2 Pt A):142-52. doi: 10.1016/j.molimm.2015.04.001. Epub 2015 Apr 28.

In vivo imaging with antibodies and engineered fragments.

Author information

1
Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, USA.
2
Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, USA. Electronic address: awu@mednet.ucla.edu.

Abstract

Antibodies have clearly demonstrated their utility as therapeutics, providing highly selective and effective drugs to treat diseases in oncology, hematology, cardiology, immunology and autoimmunity, and infectious diseases. More recently, a pressing need for equally specific and targeted imaging agents for assessing disease in vivo, in preclinical models and patients, has emerged. This review summarizes strategies for developing and optimizing antibodies as targeted probes for use in non-invasive imaging using radioactive, optical, magnetic resonance, and ultrasound approaches. Recent advances in engineered antibody fragments and scaffolds, conjugation and labeling methods, and multimodality probes are highlighted. Importantly, antibody-based imaging probes are seeing new applications in detection and quantitation of cell surface biomarkers, imaging specific responses to targeted therapies, and monitoring immune responses in oncology and other diseases. Antibody-based imaging will provide essential tools to facilitate the transition to truly precision medicine.

KEYWORDS:

Antibody fragments; Image-guided surgery; ImmunoPET; Molecular imaging

PMID:
25934435
PMCID:
PMC4529772
DOI:
10.1016/j.molimm.2015.04.001
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center